Table 2. Univariate Cox proportional hazard ratios for OS with respect to clinical parameters and HTRA1 mRNA expression levels.
| Variable | N = 129 | Numberof events | Hazard Ratio (95% CI) | p a |
| HTRA1 expression | ||||
| low | 73 | 25 | 1 | 0.023 |
| high | 56 | 12 | 0.45 (0.23–0.90) | |
| Age | ||||
| <50 | 23 | 8 | 1 | 0.444 |
| >50 | 106 | 29 | 0.74 (0.34–1.61) | |
| Menopausal status | ||||
| Pre-/peri- | 28 | 10 | 1 | 0.276 |
| postmenopausal | 101 | 27 | 0.82 (0.57–1.18) | |
| Lymph node status | ||||
| negative | 51 | 13 | 1 | 0.005 |
| 1–3 lymph nodes | 43 | 10 | 0.90 (0.40–2.07) | |
| 4–9 lymph nodes | 11 | 3 | 1.41 (0.40–4.95) | |
| >9 lymph nodes | 6 | 5 | 5.77 (2.02–16.51) | |
| unknown | 18 | |||
| Tumor stage (pT) | ||||
| 1 | 39 | 10 | 1 | 0.308 |
| 2 | 71 | 20 | 1.19 (0.56–2.55) | |
| 3+4 | 17 | 7 | 2.09 (0.79–5.52) | |
| unknown | 2 | |||
| Nuclear grading | ||||
| 1+2 | 49 | 15 | 1 | 0.896 |
| 3 | 45 | 13 | 0.95 (0.45–2.00) | |
| unknown | 35 | |||
| Estrogen receptor | ||||
| negative | 35 | 8 | 1 | 0.387 |
| positive | 91 | 28 | 1.42 (0.64–3.13) | |
| unknown | 3 | |||
| Progesterone receptor | ||||
| negative | 49 | 12 | 1 | 0.435 |
| positive | 77 | 24 | 1.32 (0.66–2.64) | |
| unknown | 3 | |||
| Adjuvant therapy | ||||
| none | 60 | 19 | 1 | 0.850 |
| endocrine only | 49 | 13 | 1.07 (0.40–2.87) | |
| chemotherapy | 20 | 5 | 0.87 (0.31–2.45) | |
a
Univariate Cox regression analysis; 95% CI, 95% confidence interval; OS, overall survival with endpoint death of any cause.